Trial Profile
Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Glatiramer acetate (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda
- 24 Dec 2023 Planned End Date changed from 31 Mar 2025 to 31 Mar 2024.
- 24 Dec 2023 Planned primary completion date changed from 31 Mar 2025 to 31 Mar 2024.
- 24 Dec 2023 Status changed from recruiting to active, no longer recruiting.